PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Study confirms adding chemotherapy to surgery improves survival in advanced gastric cancer

5 year survival data from the phase III CLASSIC trial show a 34 percent reduction in cancer mortality

2013-07-03
(Press-News.org) Lugano-Barcelona, 3 July 2013 -- For patients with advanced gastric cancer, treatment with chemotherapy after surgery can reduce the risk of cancer related death by 34% over five years compared to surgery alone, researchers said at the 15th ESMO World Congress in Gastrointestinal Cancer.

At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-year follow-up from the phase III CLASSIC trial, which added combination chemotherapy to a standard surgical procedure called D2 gastrectomy. The chemotherapy regimen studied in the trial is called XELOX, which is a combination of the drugs capecitabine and oxaliplatin.

CLASSIC was a multinational open-label randomised phase III trial performed in South Korea, China and Taiwan. Patients with stage II–IIIB gastric cancer who had undergone curative D2 gastrectomy were assigned to adjuvant XELOX for eight cycles or surgery alone. The primary endpoint was 3-year disease-free survival.

The clinical cut-off date for the prospectively planned final 5-year efficacy analysis was in November 2012. At that point, 103 (20%) patients in the XELOX group and 141 (27%) patients in the surgery alone group had died. This represented a 34% reduction in the risk of death with XELOX versus surgery alone, which is higher than the 28% reduction previously reported after three years of follow-up.

"Surgery is the most important modality in gastric cancer treatment and in the past it was considered that gastric cancer could be cured by surgery alone, if the surgery was properly performed," Dr Noh said. "However, there has been controversy over whether surgery is enough in advanced disease. The new CLASSIC data clearly shows that a XELOX regimen administered after surgery prolongs the lives of patients with gastric cancer compared to patients who had surgery alone."

The further benefits in cancer mortality risk compared to the earlier analysis are statistically significant and clinically highly relevant, Prof Noh said. "There is no doubt that XELOX is an effective therapy in the adjuvant setting."

The study also shows the importance of treatment with a multidisciplinary team of oncologists, Prof Noh said. "This work was done by collaboration between surgeons and medical oncologists. To win the war on cancer, collaboration is one of most important virtues across disciplines."

Commenting on the study, ESMO spokesperson Andrés Cervantes, Professor of Medicine at the University of Valencia, Spain, said the new findings were very important because they report mature survival data.

"Many trials reporting the effect of postoperative chemotherapy after gastrectomy for gastric cancer patients have failed in finding a significant benefit in survival," notes Dr Cervantes, who was not involved in the study. "This is a well designed trial."

Although a meta-analysis published in recent years showed that chemotherapy after a surgical resection of gastric cancer improved survival, most single studies have been negative, Dr Cervantes noted. "Having a positive study in this setting with drugs that are available in any country in Europe or even worldwide is definitely important." ### END


ELSE PRESS RELEASES FROM THIS DATE:

Study challenges long-held assumption of gene expression in embryonic stem cells

2013-07-03
CAMBRIDGE, Mass. (July 3, 2013) – Whitehead Institute researchers have determined that the transcription factor Nanog, which plays a critical role in the self-renewal of embryonic stem cells, is expressed in a manner similar to other pluripotency markers. This finding contradicts the field's presumptions about this important gene and its role in the differentiation of embryonic stem cells. A large body of research has reported that Nanog is allelically regulated—that is, only one copy of the gene is expressed at any given time—and fluctuations in its expression are responsible ...

New papers identify a microRNA that drives both cancer onset and metastasis

2013-07-03
BOSTON -- A mere 25 years ago, noncoding RNAs were considered nothing more than "background noise" in the overall genomic landscape. Now, two new studies reveal that one of these tiny noncoding molecules – microRNA-22 – plays an outsized role in two types of cancer. Reported on-line today in the journals Cell and Cell Stem Cell, the two papers demonstrate in mouse models that miR-22 drives both the onset and spread of breast cancer, as well as the onset of blood cancer. The findings, led by investigators at Beth Israel Deaconess Medical Center (BIDMC), further suggest ...

Hot flashes take heavier toll on women with HIV

2013-07-03
CLEVELAND, Ohio (July 3, 2013)—Women with HIV are living longer, so more are entering menopause. As they do, they suffer more severe hot flashes than women without HIV, and their hot flashes take a heavier toll on their quality of life and daily functioning, found researchers at Massachusetts General Hospital. Their study was published online today in Menopause, the journal of The North American Menopause Society. That toll has the potential to undermine an already shaky foundation for their lives, compromising their health, HIV treatment, and ability to abstain from ...

Immune-boosting colorectal cancer drug shows promise

2013-07-03
Lugano-Barcelona-- New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented at the ESMO 15th World Congress on Gastrointestinal Cancer. The findings confirm the biological action of the drug called MGN1703 and suggest it may be possible to identify which gastrointestinal cancer patients will benefit most from the treatment, reported Prof Hans-Joachim Schmoll from Martin Luther University, Halle, Germany. MGN1703 is a small DNA molecule recognised by a receptor --called toll-like receptor 9-- that is ...

Lifesaving HIV treatment could reach millions more people following landmark study

2013-07-03
Millions more people could get access to life-saving HIV drug therapy, following a landmark study led by Australian researchers based at the Kirby Institute at the University of New South Wales (UNSW). The researchers have found a lower daily dose of an important HIV drug therapy is safe and as effective in suppressing the virus as the standard recommended dose. The findings have been presented at the International AIDS Society Conference in Kuala Lumpur, Malaysia. "This has the potential to affect the treatment of millions of HIV positive people," says UNSW Professor ...

After millennia of mining, copper nowhere near 'peak'

2013-07-03
New research shows that existing copper resources can sustain increasing world-wide demand for at least a century, meaning social and environmental concerns could be the most important restrictions on future copper production. Researchers from Monash University have conducted the most systematic and robust compilation and analysis of worldwide copper resources to date. Contrary to predictions estimating that supplies of this important metal would run out in around 30 years, the research has found there are plenty of resources within the reach of current technologies. ...

Mobile at university -- Fit for life

2013-07-03
Jena (Germany) Spain, France and Great Britain – these are the favourite countries of young Germans who study abroad under the ERASMUS programme. More and more German students consider one or two terms at a university abroad an essential part of their CVs. As a consequence, the number of students who spent some time at a foreign university has more than doubled over the last few years and it is estimated that about a quarter of all German students have gained some form of international experiences. And that is worth it – not only in terms of university and career success. ...

Gasification method turns forest residues to biofuel with less than a euro per liter

2013-07-03
According to the new research results of the VTT Technical Research Centre of Finland, lignocellulosic biomass can be used in the production of high-quality biofuels for the price of less than one euro per litre. A new technology developed in Finland allows the transfer of more than half the energy of wood raw materials to the end-product. The technology is considered ready for the construction of a commercial-scale production plant in Europe. VTT has assessed the techno-economics of the production of renewable liquid transportation fuels from forest residues. The case ...

EULAR issues updated rheumatoid arthritis management recommendations

2013-07-03
The European League Against Rheumatism (EULAR) has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs (DMARDs) should be initiated as soon as a diagnosis of RA is made, with the aim of reaching a target of remission or low disease activity in every patient. As first-line treatment, EULAR recommends rheumatologists administer methotrexate (MTX) or combination therapy of MTX with other conventional synthetic DMARDs. Low-dose glucocorticoids should also be considered in combination ...

New evidence suggests impulsive adolescents more likely to drink heavily

2013-07-03
Scientists at the University of Liverpool have shown that young people who show impulsive tendencies are more prone to drinking heavily at an early age. The research suggests that targeting personality traits, such as impulsivity, could potentially be a successful intervention in preventing adolescent drinking from developing into problems with alcohol in later life. Studies in the UK show that approximately 24% of 12 year olds have reported at least one episode of alcohol consumption, rising to 77% of 15 year olds. Previous research has suggested that impulsive ...

LAST 30 PRESS RELEASES:

The most effective diabetes drugs don't reach enough patients yet

Breast cancer risk in younger women may be influenced by hormone therapy

Strategies for staying smoke-free after rehab

Commentary questions the potential benefit of levothyroxine treatment of mild hypothyroidism during pregnancy

Study projects over 14 million preventable deaths by 2030 if USAID defunding continues

New study reveals 33% gap in transplant access for UK’s poorest children

Dysregulated epigenetic memory in early embryos offers new clues to the inheritance of polycystic ovary syndrome (PCOS)

IVF and IUI pregnancy rates remain stable across Europe, despite an increasing uptake of single embryo transfer

It takes a village: Chimpanzee babies do better when their moms have social connections

From lab to market: how renewable polymers could transform medicine

Striking increase in obesity observed among youth between 2011 and 2023

No evidence that medications trigger microscopic colitis in older adults

NYUAD researchers find link between brain growth and mental health disorders

Aging-related inflammation is not universal across human populations, new study finds

University of Oregon to create national children’s mental health center with $11 million federal grant

Rare achievement: UTA undergrad publishes research

Fact or fiction? The ADHD info dilemma

Genetic ancestry linked to risk of severe dengue

Genomes reveal the Norwegian lemming as one of the youngest mammal species

Early birds get the burn: Monash study finds early bedtimes associated with more physical activity

Groundbreaking analysis provides day-by-day insight into prehistoric plankton’s capacity for change

Southern Ocean saltier, hotter and losing ice fast as decades-long trend unexpectedly reverses

Human fishing reshaped Caribbean reef food webs, 7000-year old exposed fossilized reefs reveal

Killer whales, kind gestures: Orcas offer food to humans in the wild

Hurricane ecology research reveals critical vulnerabilities of coastal ecosystems

Montana State geologist’s Antarctic research focuses on accumulations of rare earth elements

Groundbreaking cancer therapy clinical trial with US Department of Energy’s accelerator-produced actinium-225 set to begin this summer

Tens of thousands of heart attacks and strokes could be avoided each year if cholesterol-lowering drugs were used according to guidelines

Leading cancer and metabolic disease expert Michael Karin joins Sanford Burnham Prebys

Low-intensity brain stimulation may restore neuron health in Alzheimer's disease

[Press-News.org] Study confirms adding chemotherapy to surgery improves survival in advanced gastric cancer
5 year survival data from the phase III CLASSIC trial show a 34 percent reduction in cancer mortality